

February 5, 2019

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB
Series: EQ

Dear Sirs,

Sub: Intimation under Regulation 30(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company has received the following revised credit ratings:

Name of the Agency	Type of Credit Rating	Existing	Revised
CARE	Long-term facilities	Bank CARE BBB+ (Outlook: Stable)	CARE BBB+ (Outlook: Negative)
	Short-term facilities	Bank CARE A3+	CARE A3+

Please find enclosed a copy of the report received from the credit rating agency covering the rationale for revision in credit rating.

This is for your information and records.

Yours faithfully,
For Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary

Rating Rationale
Neuland Laboratories Limited

Ratings

Instrument	Amount (Rs. Crore)	Ratings	Rating Action
Long-term Bank Facilities	303.52	CARE BBB+; Negative (Triple B Plus; Outlook: Negative)	Reaffirmed
Short-term Bank Facilities	118.90	CARE A3+ (A Three Plus)	Reaffirmed
Total Facilities	422.42 (Rs. Four Hundred Twenty-Two Crore and Forty-Two lakhs Only)		

Detailed Rationale & Key Rating Drivers

The ratings assigned to the bank facilities of Neuland Laboratories Limited (NLL) continues to derive strength from experienced management, approved manufacturing facilities by regulatory authorities of regulated markets, capacity expansion through acquisition of manufacturing facility of Arch Pharma Labs Limited (APL), diversified product portfolio, reputed and established clientele. The ratings also factors in the successful completion of inspection by US FDA (Unit II located in Pashamylaram, Hyderabad) with no observations, improvement in liquidity profile with infusion of funds by way of qualified institutional placement (QIP) issue during May 2018. The ratings are, however, tempered by decline in total operating income and profitability margins during FY18 (refers to the period April 1 to March 31) with further deterioration in profitability margins during H1FY19, weakening of capital structure as on March 31, 2018 albeit improved as on September 30, 2018 due to QIP issue, deterioration in other debt coverage indicators and elongated operating cycle during FY18, risk associated with exchange rate fluctuation and exposure to regulatory risk.

The ability of the company to grow its revenue base and improve profitability margins, to efficiently manage its working capital requirements and its ability to timely complete repairs & refurbishment along with obtaining regulatory approvals and commence operations from its newly acquired manufacturing facility of Arch Pharma Labs Limited (APL) without availing any further external debt and thus reducing its reliance on China for procuring key intermediates shall be the key rating sensitivities.

Outlook: Negative

The negative outlook on rating of NLL reflects significant decline in the operating profit level and margin during FY18 & H1FY19 with significant increase in input prices which could not be passed on to its customers and the possibility of further deterioration for the projected period. The outlook may be

Page 2 of 12

CARE Ratings Limited

(Formerly known as Credit Analysis & Research Limited)

revised to stable if the company is able to execute the pending high margin orders and derive benefit from the backward integration unit thereby shielding the margins.

Detailed description of the key rating drivers

Experienced management and approved manufacturing facilities

NLL is led by Dr. D.R. Rao, the Chairman and MD of the company, who has over four decades of industry experience. He has a Masters in Science from Andhra University, Post Graduate Diploma in Technology from IIT Kharagpur, and was awarded his PhD in Organic Chemistry from the University of Notre Dame, U.S.A. Prior to promoting Neuland in 1984, Dr. Rao has held senior positions in R&D, production, and quality assurance at Glaxo India for about ten years. He is a member of Royal Society of Chemistry. He is ably supported by Mr. Mr. Davuluri Sucheth Rao and Mr. Davuluri Saharsh Rao. Mr. Davuluri Sucheth Rao, Vice-Chairman and Chief Executive Officer, has a degree in Mechanical Engineering and holds an MBA in Corporate Finance and Operations Management from University of Notre Dame, U.S.A. He has been actively involved in managing NLL since 2002, initially as Chief Operating Officer (COO) and then as CEO. Mr. Davuluri Saharsh Rao, Joint Managing Director, is an Electrical Engineering Graduate and obtained his Masters in Management Information Systems from Weatherhead School of Management, Cleveland, Ohio, U.S.A. He also secured Master of Business Administration from University of North Carolina, U.S.A. He joined NLL in 2007, with responsibility for initiating the Custom Manufacturing Solutions (CMS) business. He is currently responsible for all Marketing, Business Development activities along with oversight of R&D. NLL has manufacturing facilities compliant with health and regulatory agencies cGMP certifications namely, USFDA (USA), Canada (HC), PMDA (Japan), KFDA (Korea), EU (EMA), EDQM (COS) and others (ROW).

Diversified product portfolio

NLL has portfolio of 86 products (largely APIs) as on December 31, 2018 (as against 78 as on March 31, 2017). Ciprofloxacin and Levetiracetam, the flagship products of NLL continued to remain the major revenue contributor in FY18 with 19.90% share in total operating income against 22.07% share in FY17. NLL has been generating about 85% of its Total operating income from API's and remaining about 15% from Contract Manufacturing Services (CMS). With increased focus on CMS business, NLL is shifting towards low volume high margin products. The top 10 products contributed about 43.69% in FY18 against 57.55% in FY17. Further, to diversify its product portfolio the company has launched new

products and has entered new market regions during FY18. The company has also filed US DMF's for Paliperidone Palmitate Sterile, Apixaban, Aripiprazole Lauroxil and Rotigotine during FY18. The products which are expected to be scaled up during FY19 are Sugammadex Sodium, Indacaterol Maleate, Lacosamide, Apremilast, Ticagrelor and Aripiprazole Lauroxil.

Reputed and established clientele

The company has been generating revenue from customers with long standing relation with an average age of 15 years of association. The company enjoys dependable relationships with major global and Indian pharma majors. The company has established healthy relationship with reputed clients such as Teva Pharmaceutical Industries, Aurobindo Pharma Ltd, Mylan Laboratories Ltd and Azad Pharma among others. The established relations have also resulted in repeat orders from customers. No single client contributes more than 16% to the total operating revenue. Further, Top 5 clients of the company accounted for 32% during FY18 against 26.22% in FY17.

Capacity expansion through acquisition of Arch Pharma Labs Limited

The company has acquired manufacturing facility of Arch Pharma Labs Limited (APL) on December 13, 2017 which is located at Gaddapotharam Village, Medak District near Hyderabad with an installed capacity of 197 KL from JM Financial Asset Reconstruction Company Limited under SARFAESI Act. The total cost of acquisition is Rs. 118.88 crore funded through term loans of Rs. 90.20 crore, monetization of non-current investment of Rs. 20.08 crore (Nanakramguda property, Hyderabad) and internal accrual of Rs. 8.00 crore. APL has 5 production blocks for advance intermediates and API manufacturing with 70 reactors. Post-acquisition, total installed capacity of the NLL has increased from 532.70 KL (222.50 KL in unit I and 310.20 KL in unit II) to 729.70 KL. The manufacturing facility of APL was inspected by the USFDA in 2015. Currently repair & refurbishment for manufacturing facility of APL is in progress which is expected to complete by Q4FY19. Further USFDA inspection for manufacturing facility of APL is expected to be completed by December 2019 and company is expecting to commence its operations from this unit during Q4FY20. NLL has been increasing its focus towards high margin Custom Manufacturing Solutions (CMS). The acquisition of APL by NLL would support business development of CMS segment and move towards backward integration in to advance intermediates.

Decline in total operating income during FY18 albeit rebounding during H1FY19

At consolidated level, the total operating income of the company has witnessed an 8.75% decline during FY18. The total operating income declined from Rs. 579.94 crore during FY17 to Rs. 529.17 crore during

FY18 due to reduction in contribution from Ciprofloxacin and low volume high margin Custom manufacturing solutions (CMS) segment. The revenue from Ciprofloxacin has declined from Rs. 86.81 crore during FY17 to Rs. 58.03 crore during FY18. During H1FY19, the company has recorded 29.75% growth in total operating income from Rs. 250.04 crore in H1FY18 to Rs. 324.45 crore in H1FY19.

Backward integration for supporting the major products:

The company primarily relies on imports from China for its raw material requirement and faced issues w.r.t increased prices on account of closure of units in China on account of pollution norms. Given the high dependence on Chinese imports; the company had already planned a backward integration unit for production of the intermediaries. The company has identified the key raw materials/ intermediates required in production of Dorzolamide, Mirtazapine & Levetiracetam which are the prime intermediates that the company uses to manufacture its products. The aforementioned products are expected to contribute about ~20% of the total revenue during FY19. The company has already completed trial and validation batches are in progress for two intermediaries whose prices have shot up and expects to manufacture the same in house by end of Q4FY19. Apart from in house production the company has also started procuring the raw materials from alternate sources by diversifying the vendor portfolio.

Deterioration in profitability margins during FY18 and H1FY19

During FY17, high PBILDT margin was led by strong volumes of Salmeterol, Ciprofloxacin, Levetiracetam and increased revenue from CMS segment which is a low volume high margin business. During FY18, the profitability margins represented by PBILDT margin and PAT margin of the company deteriorated significantly from 18.54% and 8.08% during FY17 to 9.89% and 2.28% respectively. The decline was due to decrease in sales from high volume business such as Salmeterol, Ciprofloxacin and other high margin CMS products on account of lower offtake from its clients. Further, sales from a CMS products also have declined as the clients of the company were inhibited by regulatory authorities. Lower sales from these high volume products led to lower coverage of operating expense, thereby leading to lower PBILDT margins. Moreover, increase in major raw material costs is also attributable to decline in PBILDT margins during FY18. The company has procured about 23.82% of the raw material from China and during the year, the pollution control board had closed down manufacturing facilities in China leading to substantial demand supply gap resulting in increase in the cost of production by about 15% to 20%. During H1FY19, PBILDT margin declined to 7.82% due to further increase in raw material prices. However, CMS segment being a high margin business is expected to clock turnover of about Rs. 106.00

crore during FY19. Out of which the company has only executed orders amounting to Rs. 55.00 crore till December 31, 2018 and the remaining about Rs. 50 crore of orders are expected to be delivered during Q4FY19. Thus the execution of aforementioned CMS orders forms the critical factor from credit risk point of view.

Deterioration in overall gearing as on March 31, 2018 albeit improved as on September 30, 2018 due to QIP issue:

During FY18, the overall gearing of the company has deteriorated from 0.88x as on March 31, 2017 to 1.26x during March 31, 2018. The deterioration was mainly due to increase in term loans availed during the year. During FY18, the company has acquired manufacturing facility of Arch Pharma Labs Limited (APL) at a total purchase consideration of Rs. 118.88 crore funded through term loans of Rs. 90.20 crore, monetisation of non-current investment of Rs. 20.08 crore and internal accrual of Rs. 8.00 crore. Overall gearing of the company however has improved as on September 30, 2018 to 0.64x which is primarily attributed to QIP issue. During May 2018, to ease the liquidity position the company has issued 16,75,000 equity shares through QIP at an issue price of Rs. 750 per share amounting to Rs. 125.63 crore (including a premium of Rs. 121.68 crore). The company has utilized the aforementioned amount for pre – payment of part its long term debt amounting to Rs. 37.88 crore and balance of Rs. 87.75 crore is to be utilized for capex and working capital requirements.

Deterioration in debt coverage indicators:

Increase in debt levels due to acquisition of new unit combined with decline in profits levels during FY18 has led to deterioration in debt coverage indicators. The total debt to GCA and PBILDT interest coverage deteriorated from 3.06x and 5.10x as on March 31, 2017 to 10.92x and 2.77x as on March 31, 2018 respectively.

Moderate liquidity position

During FY18, liquidity profile of the company remained moderate with current ratio of 1.17 as on March 31, 2018. However, post QIP the liquidity profile of the company improved significantly as the company raised Rs. 125.63 crore from the issue and utilized the proceeds for pre – payment of part of its long term debt and working capital requirements. Further, the company had free cash and bank balance of Rs. 19.74 crore as on Dec 31, 2018. Further, the company has additional liquidity comfort with availability of Rs. 12 crore of CC as the company has presently availed Rs. 208.00 crore of CC out of the total sanctioned limit of Rs. 220.00 crore.

Elongated operating cycle

The total operating cycle of the company elongated from 129 days during FY17 to 169 days mainly due to increase in collection days and inventory days. The company is maintaining inventory of regular products and raw material for 90-120 days to avoid stock-out issues and providing about 80-100 days of credit period to its customer. However, the collection period during FY18 has increase as the company extended its credit period to the customers in order to retain the business relationships. Further, the company receives credit period of about 60 to 90 days from its clients. The average of maximum working capital utilization of the company for the last twelve months ending on November 2018 has been moderate at 77.96%. Nevertheless the collection period of the company has improved as on September 30, 2018 with the average collection days at 111 days as on September 30, 2018 against 131 days as on March 31, 2018.

Risk associated with exchange rate fluctuations

The total operating income of the company constitutes about 74% from export sales during FY18 (as against about 76% during FY17). Further the company has imported raw material of Rs. 76.34 crore which is about 27.58% of total raw material purchases during FY18. Accordingly NLL has natural hedge against exchange rate fluctuations to certain extent. Further, towards its hedging policy, the company is issuing bill discounting and Pre-shipment Credit in Foreign currency (PCFC) to cover about 85% of the total risk while 15% remains open. Further the company reviews and evaluates the same on a quarterly basis.

Exposure to regulatory risk

The pharmaceutical industry is highly regulated and requires various approvals, licenses, registrations and permissions for business activities. Each authority has its own requirement and they could delay or refuse to grant approval, even when a product has already been approved in another country. The approval process for a new product registration is complex, lengthy and expensive. The time taken to obtain approval varies by country but generally it takes from six months to several years from the date of application. Any delay or failure in getting approval for new product launch could adversely affect the business prospect of the company. Given, India's significant share in the US's generic market, the USFDA has increased its scrutiny of manufacturing facilities and other regulatory compliances of the Indian pharma companies supplying APIs and generic drugs to the US. Non-compliance may result in regulatory

ban on products/facilities and may impact a company's future approvals from USFDA. However, manufacturing facility of NLL is already successfully inspected Unit I by USFDA in 2018.

Prospects

Going forward, better growth in domestic sales will depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as such as cardiovascular, anti-bacterial, anti-depressants and anti-cancers with increased focus on CMS segment. The ability of the NLL to further enhance the scale of operation with the increased presence in segments like anti-cancers, cardiovascular, anti-diabetes and anti-depressants while improving the profitability margins would be key growth drivers.

Analytical Approach - Consolidated

The consolidated business and financial risk profiles of Neuland Laboratories Ltd (NLL) and its subsidiaries namely Neuland labs Inc. (USA) and Neuland Labs K.K (Japan) have been considered as these companies are subsidiaries of NLL which provide marketing support services to NLL and have financial and operational linkages.

Applicable Criteria

Criteria on assigning Outlook to Credit Ratings

CARE's Policy on Default Recognition

Criteria for Short Term Instruments

Rating Methodology-Manufacturing Companies

Financial ratios – Non-Financial Sector

Rating Methodology- Pharmaceutical Sector

About the Company

Neuland Laboratories Ltd (NLL) was set up as a private limited company in 1984 by Dr. D R Rao and Mr. G V K Rama Rao and it was reconstituted as a public limited company, with the current name, in 1994. NLL is primarily into manufacturing of active pharmaceutical ingredients for global pharmaceutical companies and also provides end-to-end solutions for the pharmaceutical industry for chemistry-related services from synthesis of library compounds to supply of New Chemical Entities (NCEs) and intermediates at various clinical phases up to commercial scale. NLL has three manufacturing facilities in and around Hyderabad, Telangana with total installed capacity of 729.70 Kilo Litre as on March 31, 2018 (222.50 KL in unit I, 310.20 KL in unit II and 195 KL in Unit III). The manufacturing facilities compliant with

Page 8 of 12

CARE Ratings Limited

(Formerly known as Credit Analysis & Research Limited)

health and regulatory agencies cGMP certifications namely, FDA (USA), Canada (HC), PMDA (Japan), KFDA (Korea), EU (EMA), EDQM (COS), ANVISA (Brazil) and others (ROW). This apart, the company also provides Custom Manufacturing Solutions (CMS) to develop and manufacture pharmaceutical ingredients and intermediates in line with customer expectations. The company has portfolio of around 86 products with presence in 25 therapeutic segments including Cardio Vascular, CNS, Ophthalmic, Antibacterial, Antidepressant, Bronchodilator, Anticonvulsant, Antipsychotics, Antiparkinsonian, Antihypertensive and Anatomical.

NLL is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). During FY18, the company received approvals from National Company Law Tribunal (NCLT) for amalgamation with its parent company (Neuland Health Sciences Private Limited, NHSPL) and its associate (Neuland Pharma Research Private Limited, NPRPL).

Financial Performance (Consolidated)

(Rs. Crore)

For the period ended / as at March31,	2016 (12m, A)	2017 (12m, A)	2018 (12m, A)
Working Results			
Total Operating income	511.34	579.94	529.17
PBILDT	81.81	107.52	52.36
Interest	24.48	21.09	18.93
Depreciation	15.74	19.23	22.10
PBT	41.06	67.19	13.93
PAT (after deferred tax)	27.08	46.86	12.06
Gross Cash Accruals	41.21	76.29	31.77
Financial Position			
Equity Capital	8.95	8.95	8.95
Networth	219.91	264.00	275.96
Total capital employed	674.36	751.98	889.20
Key Ratios			
<i>Growth</i>			
Growth in Total income (%)	8.81	13.42	-8.76
Growth in PAT (%)	69.97	73.06	-74.26
<i>Profitability</i>			
PBILDT/Total Op. income (%)	16.00	18.54	9.89
PAT (after deferred tax)/ Total income (%)	5.30	8.08	2.28
ROCE (%)	17.81	12.39	4.05
<i>Solvency</i>			
Long Term Debt Equity ratio (times)	0.21	0.16	0.43
Overall gearing ratio(times)	0.96	0.88	1.26
Interest coverage (PBILDT) (times)	3.34	5.10	2.77
Interest coverage (PBIT) (times)	2.70	4.19	1.60
Term debt/Gross cash accruals (years)	1.12	0.54	3.78
Total debt/ Gross cash accruals (years)	5.10	3.06	10.92
<i>Liquidity</i>			
Current ratio(times)	1.18	1.27	1.17
Quick ratio(times)	0.71	0.80	0.70

Page 9 of 12

CARE Ratings Limited

(Formerly known as Credit Analysis & Research Limited)

For the period ended / as at March31,	2016 (12m, A)	2017 (12m, A)	2018 (12m, A)
<i>Turnover</i>			
Avg. Collection Period (days)	89	97	131
Avg. Inventory (days)	105	102	121
Avg. Creditors (days)	82	70	83
Op. cycle (days)	112	129	169

A- Audited

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Rating History for last three years: Please refer Annexure-2

Note on complexity levels of the rated instrument: CARE has classified instruments rated by it on the basis of complexity. This classification is available at www.careratings.com. Investors/market intermediaries/regulators or others are welcome to write to care@careratings.com for any clarifications.

Analyst Contact

Name: Mr. D Naveen Kumar

Tel: 040-40102030

Mobile: +91-8886097382

Email: dnaveen.kumar@careratings.com

(This follows our brief rationale for entity published on January 30, 2019)

About CARE Ratings:

CARE Ratings commenced operations in April 1993 and over two decades, it has established itself as one of the leading credit rating agencies in India. CARE is registered with the Securities and Exchange Board of India (SEBI) and also recognized as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). CARE Ratings is proud of its rightful place in the Indian capital market built around investor confidence. CARE Ratings provides the entire spectrum of credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. Our rating and grading service offerings leverage our domain and analytical expertise backed by the methodologies congruent with the international best practices.

Disclaimer

CARE's ratings are opinions on credit quality and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE is based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors.

Annexure-1: Details of Instruments/Facilities

Name of the Instrument	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. crore)	Rating assigned along with Rating Outlook
Term Loan-Long Term	-	-	March 2026	83.52	CARE BBB+; Negative
Fund-based - LT-Working Capital Limits	-	-	-	220.00	CARE BBB+; Negative
Non-fund-based - ST-BG/LC	-	-	-	112.50	CARE A3+
Non-fund-based - ST-Forward Contract	-	-	-	6.40	CARE A3+

Annexure-2: Rating History of last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating history			
		Type	Amount Outstanding (Rs. crore)	Rating	Date(s) & Rating(s) assigned in 2018-2019	Date(s) & Rating(s) assigned in 2017-2018	Date(s) & Rating(s) assigned in 2016-2017	Date(s) & Rating(s) assigned in 2015-2016
1.	Term Loan-Long Term	LT	83.52	CARE BBB+; Negative	-	1)CARE BBB+; Stable (27-Feb-18) 2)CARE BBB+; Stable (07-Feb-18) 3)CARE BBB+; Stable (11-Apr-17)	1)CARE BBB (26-Aug-16) 2)CARE BBB- (29-Apr-16)	1)CARE BBB- (16-Sep-15) 2)CARE BBB- (07-Aug-15)
2.	Fund-based - LT-Working Capital Limits	LT	220.00	CARE BBB+; Negative	-	1)CARE BBB+; Stable (27-Feb-18) 2)CARE BBB+; Stable (07-Feb-18) 3)CARE BBB+; Stable (11-Apr-17)	1)CARE BBB (26-Aug-16) 2)CARE BBB- (29-Apr-16)	1)CARE BBB- (16-Sep-15) 2)CARE BBB- (07-Aug-15)
3.	Non-fund-based - ST-BG/LC	ST	112.50	CARE A3+	-	1)CARE A3+ (27-Feb-18) 2)CARE A3+ (07-Feb-18) 3)CARE A3+ (11-Apr-17)	1)CARE A3+ (26-Aug-16) 2)CARE A3 (29-Apr-16)	1)CARE A3 (16-Sep-15) 2)CARE A3 (07-Aug-15)
4.	Non-fund-based - ST-Forward Contract	ST	6.40	CARE A3+	-	1)CARE A3+ (27-Feb-18) 2)CARE A3+ (07-Feb-18) 3)CARE A3+ (11-Apr-17)	1)CARE A3+ (26-Aug-16) 2)CARE A3 (29-Apr-16)	1)CARE A3 (16-Sep-15) 2)CARE A3 (07-Aug-15)

Annexure-3: Details of Rated Facilities

A-1 Long-term Bank Facilities

1. Long-term Facilities

1. A. Rupee term loan

(Rs Cr)

Sr. No.	Name of the Bank	Rated amount	Remarks
1.	IndusInd Bank Limited	4.60	To repaid in 8 unequal quarterly installments from March 2019
1.	IndusInd Bank Limited	44.92	To be repaid in 28 equal installments from March 2019
2.	Aditya Birla Finance Limited	25.00	To be repaid in 28 equal installments from March 2019
3.	RBL Bank Limited	9.00 [^]	To be repaid in 13 unequal monthly installments from March 2019
	Total	83.52	

[^]considering USD/INR of Rs. 69.79

1. B. Fund-based limits

(Rs Cr)

Sr. No.	Name of the Bank	CC/FBD/FBP/PCFC*	Total fund-based limits
1.	State Bank of India	91.00	91.00
2.	Bank of India	33.00	33.00
3.	Indian Overseas Bank	29.00	29.00
4.	IndusInd Bank Limited	20.00	20.00
5.	Kotak Mahindra Bank	20.00	20.00
6.	RBL Bank Limited	15.00	15.00
7.	Proposed	12.00	12.00
	Total	220.00	220.00

*Foreign Bill Discounting/ Foreign Bill Purchase/Packing Credit in Foreign currency

Total Long-term Facilities (1.A + 1.B) Rs. 303.52 Cr

2. Long-term Facilities

2. A. Non-fund based limits

(Rs Cr)

Sr. No.	Name of the Bank	LC/BG*	Forward contracts	Total non-fund based limits
1.	State Bank of India	51.20	6.40	57.60
2.	Bank of India	13.20	-	13.20
3.	Indian Overseas Bank	21.10	-	21.10
4.	IndusInd Bank Limited	10.00	-	10.00
5.	Kotak Mahindra Bank	12.00	-	12.00
6.	Proposed	5.00	-	5.00
	Total	112.50	6.40	118.90

*Letter of Credit/ Bank Guarantee

Total short-term Facilities (2.A) Rs.118.90 Cr

Total Bank Facilities (1 + 2) Rs. 422.42 Cr

Page 12 of 12